Loading...
HVO logo

hVIVO plcAIM:HVO Stock Report

Market Cap UK£57.5m
Share Price
UK£0.094
UK£0.18
46.7% undervalued intrinsic discount
1Y-49.2%
7D19.9%
Portfolio Value
​
View

hVIVO plc

AIM:HVO Stock Report

Market Cap: UK£57.5m

hVIVO (HVO) Stock Overview

Operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America. More details

HVO fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance1/6
Financial Health6/6
Dividends2/6

Rewards

Trading at 2.4% below our estimate of its fair value

Earnings are forecast to grow 11.23% per year

Trading at good value compared to peers and industry

Risk Analysis

High level of non-cash earnings

Highly volatile share price over the past 3 months compared to the UK market

Profit margins (9.7%) are lower than last year (26%)

Does not have a meaningful market cap (£57M)


HVO Community Fair Values

Create Narrative

See what 34 others think this stock is worth. Follow their fair value or set your own to get alerts.

HVO logo
hVIVO

Canary Wharf Expansion And Automation Will Improve Efficiency Despite Risks

Key Takeaways hVIVO's operational enhancements and facility expansions aim to boost efficiency and trial capacity, potentially driving revenue and margin growth. Diversification and strategic integrations are set to enhance service offerings, reduce dependency, and strengthen long-term revenue opportunities.
View narrative
UK£0.18
FV
51.9% undervalued intrinsic discount
2.11%
Revenue growth p.a.
334
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
22users have followed this narrative
HVO logo
hVIVO

FDA Openness And Pandemic Preparedness Will Fuel Expansion

Key Takeaways Industry-leading automation and digital integration could drive greater margin expansion and cost efficiency than analysts expect as the business scales. Strong market positioning, regulatory shifts, and data asset commercialization may yield outsized, sustainable revenue growth and high-margin opportunities.
View narrative
UK£0.29
FV
70.9% undervalued intrinsic discount
8.37%
Revenue growth p.a.
25
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
HVO logo
hVIVO

Digital Trials Will Undercut Human Challenge Models But Hope Remains

Key Takeaways Rising digital and decentralized trial adoption, regulatory pressures, and industry cost-cutting threaten hVIVO's traditional market and could compress margins over time. Heavy exposure to niche markets and early-phase biotech clients increases revenue volatility and risk if client demand falters or consolidates.
View narrative
UK£0.17
FV
50.3% undervalued intrinsic discount
-2.25%
Revenue growth p.a.
32
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
View Stock Community
UNCY logo
Unicycive Therapeutics

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more

View narrative
5.9k
users have viewed this narrative
17users have liked this narrative
0users have commented on this narrative
113users have followed this narrative
US$21.53
67.6% undervalued intrinsic discount
Fair Value
Profit Margin
20%
Future PE
27x
Price in 2030
US$34.67

hVIVO plc Competitors

Price History & Performance

Summary of share price highs, lows and changes for hVIVO
Historical stock prices
Current Share PriceUK£0.085
52 Week HighUK£0.20
52 Week LowUK£0.043
Beta1.67
1 Month Change8.33%
3 Month Change42.02%
1 Year Change-49.17%
3 Year Change-52.39%
5 Year Change-77.76%
Change since IPO24.26%

Recent News & Updates

Recent updates

User avatar

Expansion Into New Canary Wharf Facility Will Increase Capacity But Challenges In Sustaining Margins May Arise

Expansion into a new facility and offering new services are expected to drive revenue growth and diversify income streams.

hVIVO plc's (LON:HVO) Intrinsic Value Is Potentially 28% Above Its Share Price

Jan 26
hVIVO plc's (LON:HVO) Intrinsic Value Is Potentially 28% Above Its Share Price

Improved Revenues Required Before hVIVO plc (LON:HVO) Stock's 26% Jump Looks Justified

Jan 03
Improved Revenues Required Before hVIVO plc (LON:HVO) Stock's 26% Jump Looks Justified

At UK£0.20, Is hVIVO plc (LON:HVO) Worth Looking At Closely?

Nov 30
At UK£0.20, Is hVIVO plc (LON:HVO) Worth Looking At Closely?

A Piece Of The Puzzle Missing From hVIVO plc's (LON:HVO) Share Price

Jun 14
A Piece Of The Puzzle Missing From hVIVO plc's (LON:HVO) Share Price

A Look At The Intrinsic Value Of hVIVO plc (LON:HVO)

Feb 01
A Look At The Intrinsic Value Of hVIVO plc (LON:HVO)

Should You Investigate hVIVO plc (LON:HVO) At UK£0.11?

Dec 20
Should You Investigate hVIVO plc (LON:HVO) At UK£0.11?

Is There An Opportunity With Open Orphan Plc's (LON:ORPH) 41% Undervaluation?

Sep 13
Is There An Opportunity With Open Orphan Plc's (LON:ORPH) 41% Undervaluation?

Are Investors Undervaluing Open Orphan plc (LON:ORPH) By 44%?

Jun 02
Are Investors Undervaluing Open Orphan plc (LON:ORPH) By 44%?

Introducing Open Orphan (LON:ORPH), The Stock That Soared 388% In The Last Year

Feb 15
Introducing Open Orphan (LON:ORPH), The Stock That Soared 388% In The Last Year

How Much Of Open Orphan plc (LON:ORPH) Do Insiders Own?

Dec 23
How Much Of Open Orphan plc (LON:ORPH) Do Insiders Own?

Calculating The Fair Value Of Open Orphan plc (LON:ORPH)

Nov 18
Calculating The Fair Value Of Open Orphan plc (LON:ORPH)

Shareholder Returns

HVOGB Life SciencesGB Market
7D19.9%1.9%-0.2%
1Y-49.2%-2.5%27.3%

Return vs Industry: HVO underperformed the UK Life Sciences industry which returned -8.9% over the past year.

Return vs Market: HVO underperformed the UK Market which returned 28.2% over the past year.

Price Volatility

Is HVO's price volatile compared to industry and market?
HVO volatility
HVO Average Weekly Movement12.5%
Life Sciences Industry Average Movement9.1%
Market Average Movement5.6%
10% most volatile stocks in GB Market12.0%
10% least volatile stocks in GB Market3.1%

Stable Share Price: HVO's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: HVO's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a301Mo Khanwww.hvivo.com

hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including assay development, cell based assays, molecular, immunology, virology, clinical field trail logistics, and biomarker analysis services. It has a portfolio of human challenge study models for conditions, such as RSV, influenza, COVID-19, hMPV, HRV, asthma, malaria, and COPD.

hVIVO plc Fundamentals Summary

How do hVIVO's earnings and revenue compare to its market cap?
HVO fundamental statistics
Market capUK£57.49m
Earnings (TTM)UK£5.28m
Revenue (TTM)UK£54.47m
10.9x
P/E Ratio
1.1x
P/S Ratio

Is HVO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HVO income statement (TTM)
RevenueUK£54.47m
Cost of RevenueUK£43.77m
Gross ProfitUK£10.70m
Other ExpensesUK£5.42m
EarningsUK£5.28m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)0.0078
Gross Margin19.64%
Net Profit Margin9.70%
Debt/Equity Ratio0%

How did HVO perform over the long term?

See historical performance and comparison

Dividends

2.4%
Current Dividend Yield
26%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/15 14:02
End of Day Share Price 2026/04/15 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

hVIVO plc is covered by 11 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael MitchellCavendish
Christopher DonnellanCavendish
Edward ThomasonCGS International